Dacomitinib

Entry

D10514                      Drug

Name

Dacomitinib (USAN);
Dacomitinib hydrate (JAN);
Vizimpro (TN)

Product

VIZIMPRO (Pfizer Laboratories Div Pfizer), VIZIMPRO (U.S. Pharmaceuticals)

Formula

C24H25ClFN5O2. H2O

Exact mass

487.1786

Mol weight

487.9543

Structure

Simcomp

Class

Antineoplastic
DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
   DG03162  EGFR inhibitor
Metabolizing enzyme inhibitor
DG01645  CYP2D6 inhibitor

Remark

Therapeutic category:

4291

ATC code:

L01EB07

Chemical structure group:

DG01793

Product (DG01793):

D10514<JP/US>

Efficacy

Antineoplastic, Receptor tyrosine kinase inhibitor

Disease

Non-small cell lung cancer (EGFR mutation positive) [DS:H00014]

Target

EGFR* [HSA_VAR:1956v2] [HSA:1956] [KO:K04361]
ERBB2 (HER2, CD340) [HSA:2064] [KO:K05083]
ERBB4 (HER4) [HSA:2066] [KO:K05085]

Network

N10005

First/second-generation tyrosine kinase inhibitor to EGFR mutation

Pathway

hsa04012

ErbB signaling pathway

hsa04020

Calcium signaling pathway

hsa05205

Proteoglycans in cancer

Interaction

CYP inhibition: CYP2D6 [HSA:1565]

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01E PROTEIN KINASE INHIBITORS
    L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
     L01EB07 Dacomitinib
      D10514  Dacomitinib (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
  Molecular Target Inhibitors
   Dacomitinib
    D10514  Dacomitinib (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10514  Dacomitinib (USAN); Dacomitinib hydrate (JAN)
Drug groups [BR:br08330]
Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03162  EGFR inhibitor
     DG01793  Dacomitinib
      D10514  Dacomitinib
Metabolizing enzyme inhibitor
  DG01645  CYP2D6 inhibitor
   DG01793  Dacomitinib
    D10514  Dacomitinib
Drug classes [BR:br08332]
Antineoplastic
  DG03162  EGFR inhibitor
   D10514  Dacomitinib
Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   EGFR family
    EGFR* [HSA_VAR:1956v2]
     D10514  Dacomitinib (USAN) <JP/US>
    ERBB2 (HER2, CD340)
     D10514  Dacomitinib (USAN) <JP/US>
    ERBB4 (HER4)
     D10514  Dacomitinib (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D10514
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D10514
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D10514
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D10514
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D10514
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
  D10514
Drug groups [BR:br08330]
Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG03162  EGFR inhibitor
     DG01793  Dacomitinib
Metabolizing enzyme inhibitor
  DG01645  CYP2D6 inhibitor
   DG01793  Dacomitinib

Other DBs

CAS:	1042385-75-0

PubChem:

172232607

KCF data

ATOM        34
            1   C8y C    21.0000  -13.9300
            2   C8y C    21.0000  -15.3300
            3   C8x C    22.1900  -16.0300
            4   C8y C    23.3800  -15.3300
            5   C8y C    23.3800  -13.9300
            6   C8x C    22.1900  -13.2300
            7   C8y C    24.6400  -16.0300
            8   N5x N    25.8300  -15.3300
            9   C8x C    25.8300  -13.9300
            10  N5x N    24.6400  -13.2300
            11  N1b N    19.7400  -16.0300
            12  C5a C    19.7400  -17.4300
            13  O2a O    19.7400  -13.2300
            14  C1a C    18.5500  -13.8600
            15  C2b C    18.5500  -18.1300
            16  O5a O    21.0000  -18.1300
            17  C2b C    17.3600  -17.4300
            18  C1b C    16.1700  -18.1300
            19  N1y N    14.9800  -17.4300
            20  C1x C    14.9800  -16.0300
            21  C1x C    13.7900  -15.3300
            22  C1x C    12.5300  -16.0300
            23  C1x C    12.5300  -17.4300
            24  C1x C    13.7900  -18.1300
            25  N1b N    24.6400  -17.4300
            26  C8y C    25.8300  -18.1300
            27  C8x C    25.8300  -19.5300
            28  C8x C    27.0200  -20.2300
            29  C8y C    28.2800  -19.5300
            30  C8y C    28.2800  -18.1300
            31  C8x C    27.0200  -17.4300
            32  X   Cl   29.4700  -17.4300
            33  X   F    29.4700  -20.2300
            34  O0  O    29.4700  -13.7900
BOND        36
            1     1   2 1
            2     2   3 2
            3     3   4 1
            4     4   5 2
            5     5   6 1
            6     1   6 2
            7     4   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11    5  10 1
            12    2  11 1
            13   11  12 1
            14    1  13 1
            15   13  14 1
            16   12  15 1
            17   12  16 2
            18   15  17 2
            19   17  18 1
            20   18  19 1
            21   19  20 1
            22   20  21 1
            23   21  22 1
            24   22  23 1
            25   23  24 1
            26   19  24 1
            27    7  25 1
            28   25  26 1
            29   26  27 1
            30   27  28 2
            31   28  29 1
            32   29  30 2
            33   30  31 1
            34   26  31 2
            35   30  32 1
            36   29  33 1